QGEN - QIAGEN N.V.
| Previous Close | 40.37 |
| Open | 40.17 |
| Bid | 40.02 x 1000 |
| Ask | 40.02 x 1100 |
| Day's Range | 39.90 - 40.35 |
| 52 Week Range | 32.33 - 41.55 |
| Volume | 420,929 |
| Avg. Volume | 1,198,095 |
| Market Cap | 9.088B |
| Beta (3Y Monthly) | 0.85 |
| PE Ratio (TTM) | 49.43 |
| EPS (TTM) | 0.81 |
| Earnings Date | Jul 30, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 42.50 |
- Business Wire•6 days ago
QIAGEN Clinical Insight Surpasses 1 Million Patient Test Cases Analyzed and Interpreted
Industry-leading bioinformatics software delivers genomic insights for precision medicine
- Zacks•6 days ago
QIAGEN Inks Distribution Deal With Mckesson Medical-Surgical
The distribution agreement will enable QIAGEN (QGEN) to expand reach in the healthcare market.
- Business Wire•7 days ago
QIAGEN and McKesson Agree to Distribute QIAstat-Dx Syndromic Testing Solution to Smaller Hospitals and Other Select Segments in the United States
Frankfurt Prime Standard: QIA) today announced an agreement for McKesson Medical-Surgical Inc., an affiliate of McKesson Corporation , a global leader in healthcare supply chain management solutions, to serve as the exclusive distributor of QIAGEN’s QIAstat-Dx syndromic testing solution in the “acute” market segment of U.S. hospitals with 200 beds or less and in other select segments. The agreement also makes McKesson a non-exclusive distributor for future expansion of QIAstat-Dx into the non-acute retail clinics located in U.S. retail pharmacies.
- Simply Wall St.•9 days ago
Is QIAGEN N.V. (NYSE:QGEN) Overpaying Its CEO?
Peer Schatz has been the CEO of QIAGEN N.V. (NYSE:QGEN) since 2004. This analysis aims first to contrast CEO...
- Insider Monkey•13 days ago
Here’s What Hedge Funds Think About Qiagen NV (QGEN)
How do we determine whether Qiagen NV (NYSE:QGEN) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows that […]
- Zacks•15 days ago
Here's Why You Should Hold on to QIAGEN (QGEN) Stock Now
QIAGEN (QGEN) is enjoying investors' high confidence, courtesy of the QIAstat-Dx system.
- Markit•16 days ago
See what the IHS Markit Score report has to say about Qiagen NV.
Qiagen NV NYSE:QGENView full report here! Summary * ETFs holding this stock have seen outflows over the last one-month * Bearish sentiment is low * Economic output for the sector is expanding but at a slower rate Bearish sentimentShort interest | PositiveShort interest is low for QGEN with fewer than 5% of shares on loan. The last change in the short interest score occurred more than 1 month ago and implies that there has been little change in sentiment among investors who seek to profit from falling equity prices. Money flowETF/Index ownership | NegativeETF activity is negative. Over the last one-month, outflows of investor capital in ETFs holding QGEN totaled $694 million. Additionally, the rate of outflows appears to be accelerating. Economic sentimentPMI by IHS Markit | NegativeAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is weak relative to the trend shown over the past year, however, and is easing. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to score@ihsmarkit.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
- Zacks•20 days ago
QIAGEN-DiaSorin Union to Enhance QuantFERON for Lyme Disease
QIAGEN (QGEN) expects multi-site clinical validations for this new system during 2020 Lyme disease season.
- Zacks•21 days ago
Qiagen (QGEN) Up 4% Since Last Earnings Report: Can It Continue?
Qiagen (QGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Business Wire•21 days ago
QIAGEN and DiaSorin collaborate on novel QuantiFERON-based test with breakthrough potential for earlier detection of Lyme disease
Frankfurt Prime Standard: QIA) and DiaSorin (FTSE MIB: DIA) today announced the expansion of their QuantiFERON collaboration to develop an ultra-sensitive diagnostic test for Lyme disease, which is expected to address a significant unmet medical need. The QuantiFERON technology comes in two components: the QuantiFERON sample collection component with the proprietary assay stimulus/initiation and QuantiFERON read-out component to measure the signal created by the stimulus.
- Simply Wall St.•27 days ago
At US$37.76, Is It Time To Put QIAGEN N.V. (NYSE:QGEN) On Your Watch List?
QIAGEN N.V. (NYSE:QGEN), which is in the life sciences business, and is based in Netherlands, saw significant share...
- Zacks•27 days ago
Should You Invest in the Invesco Dynamic Biotechnology & Genome ETF (PBE)?
Sector ETF report for PBE
- Zacks•29 days ago
QIAGEN (QGEN) Launches PIK3CA Kit for Breast Cancer Patients
QIAGEN's (QGEN) therascreen PIK3CA Kit is the first companion diagnostic test to have attained premarket approval from the FDA.
- Business Wire•last month
QIAGEN launches first FDA-approved companion diagnostic for PIK3CA biomarkers to enhance precision medicine in breast cancer
Innovative therascreen® PIK3CA RGQ PCR Kit receives U.S. regulatory approval for use in guiding treatment decisions from tissue and liquid biopsy for newly approved therapy PIQRAY®
- Zacks•last month
QIAGEN (QGEN) to Win U. N. Accolade for QuantiFERON-TB Access
This acclaim marks a giant leap for QIAGEN (QGEN) in the field of tuberculosis diagnosis.
- Business Wire•last month
QIAGEN’s QuantiFERON®-TB Access development program gains recognition from United Nations initiative for health innovation
New breakthrough test for low-resource, high-burden regions to help in global fight against tuberculosis
- Associated Press•last month
Sprint and Qiagen rise while Apple and Dish decline
Stocks that moved substantially or traded heavily on Monday: Alphabet Inc., down $24.12 to $1,144.66 The parent of search engine Google warned that some of its features could lose support on Huawei mobile ...
- Benzinga•last month
Qiagen Snags FDA Nod For Molecular Diagnostic System, Announces US Launch
Qiagen NV (NYSE: QGEN ) shares were spiking higher Monday following the announcement of FDA approval for its molecular diagnostic testing system. What Happened Germany-based Qiagen, a provider of sample ...
- Zacks•last month
QIAGEN Partners Inovio to Develop Companion Diagnostics
QIAGEN's (QGEN) Sample to Insight workflows and expertise in developing diagnostic solutions will aptly compliment Inovio regarding Precision Medicine in immuno-oncology.
- Benzinga•last month
The Daily Biotech Pulse: Axovant Doses First Patient In Gene Therapy Trial, Agile Resubmits NDA, ADMA Prices Offering
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on May 16) Adverum Biotechnologies Inc (NASDAQ: ADVM )(announced ...
- PR Newswire•last month
Inovio and QIAGEN Establish Collaboration to Develop Diagnostic Test for VGX-3100, Inovio's Novel Immunotherapy Targeting Advanced Cervical Pre-Cancer
Frankfurt Prime Standard: QIA) today announced a collaboration to co-develop a diagnostic test to identify patients most likely to respond to VGX-3100, Inovio's immunotherapy to treat advanced cervical dysplasia associated with the human papillomavirus virus (HPV). This precision medicine partnership focuses on Inovio's VGX-3100, a late-stage product candidate currently in two pivotal Phase 3 clinical trials (REVEAL 1 and 2) with potential to become the first treatment for HPV infection of the cervix and the first non-surgical treatment for precancerous cervical lesions associated with the virus.
